RxDoctor Payments Data

Barbara Parks, MD

Internal Medicine · Virginia Beach, VANPI 1871656819

Payments from drug & device makers

$9,293in general payments, 2019–2025

Across 81 payments — averaging $114.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascendis Pharma Endocrinology Inc$8K
  • Sanofi-aventis U.S. LLC$225
  • Tris Pharma Inc$175
  • AstraZeneca$174
  • Amgen$164
  • Abbott$132
  • plus $735 from 14 others

What the payments were for

  • Food & beverage$1,605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,293 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$58,251
Medicare patients
80
Services billed
568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$108,854
JanuviaSitagliptin Phosphate33$29,669
OzempicSemaglutide22$25,841
XareltoRivaroxaban23$16,531
FarxigaDapagliflozin Propanediol12$14,496
LinzessLinaclotide18$13,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,092
EntrestoSacubitril/Valsartan14$9,577
XiidraLifitegrast13$8,969
Arnuity ElliptaFluticasone Furoate16$5,981
PremarinEstrogens, Conjugated17$5,329
PaxlovidNirmatrelvir/Ritonavir31$4,288
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,868
SynthroidLevothyroxine Sodium24$2,718
Levothyroxine Sodium139$1,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$119$118,471149 claims
Novo NordiskOzempic$71$25,84122 claims
GSKTrelegy Ellipta, Arnuity Ellipta$58$18,07334 claims
AbbVieLinzess, Synthroid, Armour Thyroid$93$17,64854 claims
AstraZenecaFarxiga$174$14,49612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →